The complex of these metabolic activities confirms the pleiotropic activity of FGF21, improving insulin sensitivity, hepatic steatosis, and body weight and leading to its recognition as a potential therapeutic target for obesity-related metabolic disorders, including NAFLD/MASLD [53]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.